Bladder Cancer Treatment Market: By Cancer Type (Transitional Cell Bladder Cancer, Invasive Bladder Cancer, Superficial Bladder Cancer, Squamous Cell Bladder Cancer, Other Rare Types), By Drug Class (Chemotherapy And Immunotherapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) And By Geography  

Bladder Cancer Treatment Market size was valued at 3.6 billion in 2022 and is expected to reach 4.8 billion by 2029, at a CAGR of 4.3% from 2023 to 2029. Bladder cancer is a disease in which malignant cells are formed in the tissues of the bladder. Symptoms of bladder cancer include blood in the urine, pain with urination, and low back pain. There are three types of bladder cancer that begin in the cells in the lining of the bladder. They are named transitional cell carcinoma, squamous cell carcinoma, and adenocarcinoma. As per the National Institute of Health, approximately 17,000 women and 45,000 men every year are diagnosed with bladder cancer in the U.S. only. The market for bladder cancer is rapidly increasing and it is anticipated to grow rapidly from 2016 to 2022 globally. According to The American Cancer Society, in 2017, estimated bladder cancers in the United States 79,030 new cases (about 60,490 in men and 18,540 in women) were diagnosed, and about 16,870 deaths from bladder cancer (about 12,240 in men and 4,630 in women). Bladder cancer accounts for about 5% of all new cancers in the US. It is the fourth most common cancer in men, but it is less common in women. In addition, the rise in awareness about bladder cancer and its available treatment options in the market, innovation in drug development, and subsequent technological advancements are expected to drive the market for bladder cancer treatment drugs. An increasing number of mergers and acquisitions, the rise in the number of collaborations and partnerships, new product launches, and growing awareness about the availability of bladder cancer treatment drugs are some of the latest trends that have been observed in the market.